Pfizer Inc. raised its full-year adjusted profit guidance after reporting better-than-expected results for the second quarter of 2025. The company's revenues reached $14.65 billion, a 10% increase from the prior-year period, surpassing Wall Street estimates.
Adjusted diluted earnings per share (EPS) for the quarter were $0.78, exceeding expectations. Reported net income was $2.91 billion, or $0.51 per share, a significant improvement from $41 million, or $0.01 per share, in Q2 2024.
Pfizer now expects full-year 2025 adjusted profit to be between $2.90 and $3.10 per share, up from previous guidance of $2.80 to $3.00. The company maintained its 2025 revenue forecast of $61.0 billion to $64.0 billion, which includes a one-time charge of $1.35 billion related to a licensing deal with China's 3SBio.
Revenue growth was driven by strong demand for the Vyndaqel family, Comirnaty ($381 million, up 96%), and Paxlovid ($427 million, up 70%), as well as contributions from Padcev and Eliquis. The company reiterated its expectation to deliver $7.7 billion in cost savings by the end of 2027, demonstrating disciplined financial management amidst ongoing drug pricing pressures and tariff threats.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.